Description: Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics. The Company’s pipeline aims to disrupt existing treatment paradigms and features several new molecular entities that inhibit novel targets with first-in-class potential for autoimmune, inflammatory, and other debilitating diseases. Fresh Track Therapeutic’s executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization, having served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first-in-class products that achieved iconic status, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. The Company’s strategy is to align this experience and clear vision to explore beyond the limitations of current therapies by identifying, pursuing, and developing next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with autoimmune, inflammatory, and other debilitating diseases.
Home Page: ir.frtx.com
FRTX Technical Analysis
2000 Central Avenue
Boulder,
CO
80301
United States
Phone:
720 505 4755
Officers
Name | Title |
---|---|
Mr. Albert Nicholas Marchio II | CEO, CFO, Secretary & Chairman |
Aron Aizenstat M.B.A., P.M.P. | Vice President of Corporate Development & Operations |
Mr. Aaron Fox-Collis CPA | VP of Finance & Chief Accounting Officer |
Ms. Sue Fattor | Head of Human Resource |
Dr. James S. McElvain Ph.D. | Interim Head of CMC Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.4512 |
Price-to-Sales TTM: | 0.5596 |
IPO Date: | 2022-09-08 |
Fiscal Year End: | December |
Full Time Employees: | 4 |